We are live on ! Find out more
TVTX icon

Travere Therapeutics

174 hedge funds and large institutions have $736M invested in Travere Therapeutics in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 49

8% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 26

2% more capital inflows, than outflows

Capital inflows: $77.9M | Capital outflows: $76.4M

0% more funds holding

Funds holding: 174 → 174 (0)

1.82% less ownership

Funds ownership: 116.95% → 115.14% (-1.8%)

52% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $3.75M

Holders
174
Holders Change
–
Holders Change %
0%
% of All Funds
2.51%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
28
Increased
70
Reduced
49
Closed
26
Calls
$1.81​M
Puts
$3.75​M
Net Calls
-⁠$1.94​M
Net Calls Change
+$2.78​M

TVTX Hedge Fund Activity: Q2 2024 in Review

174 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2024, worth a combined $736M — up 8.8% from $677M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new TVTX positions and 26 closed out — a net gain of 2 holders — while 70 added to existing stakes and 49 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $13.4M. The largest seller was State Street, cutting an estimated $20.9M.

  • 174 institutional investors held Travere Therapeutics (TVTX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $736M of Travere Therapeutics stock for Q2 2024, up 8.8% quarter-over-quarter.
  • 28 funds opened new Travere Therapeutics positions in Q2 2024 and 26 closed out, a net change of +2 holders.
  • The largest Travere Therapeutics buyer in Q2 2024 was Assenagon Asset Management, an estimated $13.4M added.
  • The largest Travere Therapeutics seller in Q2 2024 was State Street, an estimated $20.9M sold.

Based on aggregated 13F filings for Q2 2024.